Prof. Dr. rer. nat. Hiltrud Brauch

Associated Professor 

Department of Clinical Pharmacology, University of Tübingen


Deputy Head of the Dr. Margarete Fischer-Bosch Institute of

Clinical Pharmacology, Stuttgart

Auerbachst. 12

D-70193 Stuttgart, Germany

Phone: +49-711-81013705

Email: hiltrud.brauch[at]  /




Download CV


10 most relevant publications



Breast cancer is the most frequent female cancer with more than one million newly diagnosed cases and more than 350.000 women dying from the disease each year worldwide. This is mainly attributed to the lack of known risk factors as well as lack of efficient and non-toxic anti-cancer drugs. My research employs strategies that might help to cut down the incidence of breast cancer by way of molecular epidemiological studies and to improve treatment outcomes of available therapies by way of pharmacogenomic approaches. My research team employs large patient collections (case-control and treatment cohorts) for the identification of susceptibility genes and treatment predictors by candidate gene, whole genome as well as epigenetic approaches. Candidates are further explored in mechanistic studies to establish biological evidence. This translational research involves a high degree of interdisciplinary collaboration among scientists with medical, epidemiological, laboratory and statistical expertises for the complex evaluation of clinical and laboratory data obtained via high-throughput molecular analyses. The overall goal is to provide the knowledge and diagnostic tools for future exploration and implementation of personalized treatment schemes.

Research Interests

  • Candidate and genome wide search for breast cancer susceptibility genes
  • Genotype – phenotype correlations for the description of breast cancer subtypes
  • Tamoxifen pharmacogenomics and translation
  • Estrogen receptor regulation
  • Pharmacogenomics of anti cancer drugs
  • Epigenetic approaches for the identification of novel treatment predictors and drug targets
  • Breast cancer susceptibility
  • Breast cancer pharmacogenomics
  • Target identification to overcome endocrine resistance
  • Biomarker development for breast cancer management
  • Novel drug concepts for the improvement of endocrine therapy


Joint Research Projects

2016 – 2019:  

Konsortialprojekt “Verbesserte endokrine Therapie beim Mammakarzinom: Machbarkeitsnachweis der Supplementierung einer Standardtamoxifentherapie mit dem aktiven Metaboliten Endoxifen“, BMBF